awmsg logo



rilpivirine (Edurant®)


Reference No. 557

Publication date:
27/07/2012


Last review date:
30/08/2016

Appraisal information

rilpivirine (Edurant®) 25 mg film-coated tablet


Company: Janssen-Cilag Ltd
BNF category: Infections
NMG meeting date: 15/05/2012
AWMSG meeting date: 20/06/2012
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1312
Ministerial ratification: 23/07/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Rilpivirine (Edurant®) is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml, in combination with other antiretroviral medicinal products.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download